Kaplan-Meier curves showing progression-free survival in the intent-to-treat population and by number of prior lines of therapy. PFS overall (A; primary end point; ITT population) and by number of prior LoT (B; prespecified subgroup analysis, per protocol; ITT population). PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-cel infusion. PFS based on IMWG criteria per IRC. ∗Based on KM approach. †Stratified HR based on univariate Cox proportional hazard model. CI is 2-sided. IMWG, International Myeloma Working Group; SE, standard error.